| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2005 | EP1500393A1 Injectable composition containing taxol |
| 01/26/2005 | EP1500392A1 Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions |
| 01/26/2005 | EP1500391A1 Therapeutic use of bicycloheptane derivatives |
| 01/26/2005 | EP1500389A1 Biofilm removing agent |
| 01/26/2005 | EP1500331A1 Microbicidal composition |
| 01/26/2005 | EP1499746A1 Method to inhibit cell growth using oligonucleotides |
| 01/26/2005 | EP1499742A1 Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499623A1 Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one |
| 01/26/2005 | EP1499622A1 Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors |
| 01/26/2005 | EP1499621A1 Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors |
| 01/26/2005 | EP1499619A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof |
| 01/26/2005 | EP1499618A1 Furyl compounds |
| 01/26/2005 | EP1499617A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| 01/26/2005 | EP1499616A1 Heterocyclic compounds |
| 01/26/2005 | EP1499615A1 Thienyl compounds |
| 01/26/2005 | EP1499614A1 Adenosine a3 receptor modulators |
| 01/26/2005 | EP1499613A1 Thioxanthine derivatives as myeloperoxidase inhibitors |
| 01/26/2005 | EP1499612A1 Piperidine ouracil used as a medicament for treating bacterial infections |
| 01/26/2005 | EP1499611A1 Process for 5- 2(r)- 1(r)- 3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one |
| 01/26/2005 | EP1499610A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 01/26/2005 | EP1499609A2 Pesticidal heterocycles |
| 01/26/2005 | EP1499608A1 Substituted imidazole derivatives: gaba a receptor ligands |
| 01/26/2005 | EP1499607A1 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists |
| 01/26/2005 | EP1499606A1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499603A1 Antiviral lactone-ureas |
| 01/26/2005 | EP1499601A1 New 2-substituted -1,3-thiazole compounds |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 01/26/2005 | EP1499599A1 Substituted pyrazine derivatives |
| 01/26/2005 | EP1499598A1 Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| 01/26/2005 | EP1499597A2 Compounds and methods for inducing apoptosis in proliferating cells |
| 01/26/2005 | EP1499595A1 Amonafide salts |
| 01/26/2005 | EP1499594A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
| 01/26/2005 | EP1499593A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
| 01/26/2005 | EP1499592A1 Amlodipine nicotinate and process for the preparation thereof |
| 01/26/2005 | EP1499591A1 Carboxylic acid amides |
| 01/26/2005 | EP1499589A1 Derivatives of n-phenyl(piperidin-2-yl)methyl benzamide, the preparation method thereof and application of same in therapeutics |
| 01/26/2005 | EP1499588A1 Melanocortin receptor ligands |
| 01/26/2005 | EP1499586A1 Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| 01/26/2005 | EP1499585A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 01/26/2005 | EP1499583A1 Process for preparing highly functionalized y-butyrolactams and y-amino acids |
| 01/26/2005 | EP1499582A1 Method for chlorinating tertiary alcohols |
| 01/26/2005 | EP1499581A1 Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
| 01/26/2005 | EP1499580A1 Compounds that stimulate glucose utilization and methods of use |
| 01/26/2005 | EP1499578A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 01/26/2005 | EP1499577A1 2-(2,6-dichlorophenyl)-diarylimidazoles |
| 01/26/2005 | EP1499369A1 Stents containing pyridine-substituted pyrazolopyridine derivatives |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499357A1 Treatment of metabolic syndrome |
| 01/26/2005 | EP1499353A2 Antibodies that specifically bind to tl5 |
| 01/26/2005 | EP1499351A2 Antibodies that specifically bind to tr2 |
| 01/26/2005 | EP1499350A2 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 01/26/2005 | EP1499338A1 7-hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof |
| 01/26/2005 | EP1499331A2 Salt solution for colon cleansing |
| 01/26/2005 | EP1499327A2 Beta -amyloid peptide-binding proteins and polynucleotides encoding the same |
| 01/26/2005 | EP1499326A1 Oxolide antibacterials |
| 01/26/2005 | EP1499325A1 Methods and compositions for inhibition of irritation by disaccharide and metal ions |
| 01/26/2005 | EP1499324A1 Method for treating and preventing hyperparathyroidism |
| 01/26/2005 | EP1499323A1 Treatment of hypertension in women receiving hormone replacement therapy |
| 01/26/2005 | EP1499322A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy |
| 01/26/2005 | EP1499321A2 Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") |
| 01/26/2005 | EP1499320A1 Novel compounds |
| 01/26/2005 | EP1499319A1 Bicyclo 4.4.0 antiviral derivatives |
| 01/26/2005 | EP1499317A1 Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
| 01/26/2005 | EP1499316A1 (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists |
| 01/26/2005 | EP1499315A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia |
| 01/26/2005 | EP1499314A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders |
| 01/26/2005 | EP1499313A2 Heterocyclic derivatives as opioid receptor modulators |
| 01/26/2005 | EP1499312A1 The use of hydroxypyridone-derivatives in wound healing |
| 01/26/2005 | EP1499311A1 Substituted benzazoles and use thereof as raf kinase inhibitors |
| 01/26/2005 | EP1499310A2 Carvedilol monocitrate monohydrate |
| 01/26/2005 | EP1499309A1 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 01/26/2005 | EP1499308A2 Tri-substituted heteroaryls and methods of making and using the same |
| 01/26/2005 | EP1499307A1 Low-pressure mercury vapor discharge lamp |
| 01/26/2005 | EP1499306A2 Bicyclic amides |
| 01/26/2005 | EP1499305A2 Use of ep4 receptor ligands in the treatment of il-6 involved diseases |
| 01/26/2005 | EP1499304A1 Liquid compositions for soft sustained-release capsules and method for production thereof |
| 01/26/2005 | EP1499303A2 Multi-phase, multi-compartment capsular system |
| 01/26/2005 | EP1499301A2 Method of stabilizing bupropion hydrochloride tablets |
| 01/26/2005 | EP1499299A2 Microparticle pharmaceutical compositions for intratumoral delivery |
| 01/26/2005 | EP1499298A1 Oral administration form for difficulty soluble basic active ingredients which are applied orally |
| 01/26/2005 | EP1499297A2 Pharmaceutical formulation comprising atorvastatin calcium |
| 01/26/2005 | EP1499295A1 Sustained release metoprolol formulations |
| 01/26/2005 | EP1499294A2 Transport system in biological systems |
| 01/26/2005 | EP1499293A2 Topical application of alpha-dfmo and anti-inflammatory drug for treatment of actinic keratoses |
| 01/26/2005 | EP1499291A1 Methods and dosage forms for controlled delivery of oxycodone |
| 01/26/2005 | EP1499290A1 Warming and nonirritating lubricant compositions |
| 01/26/2005 | EP1499289A2 Volume efficient controlled release dosage form |
| 01/26/2005 | EP1499278A1 Immediate-release pharmaceutical dosage form comprising polymorphous tibolone |
| 01/26/2005 | EP1499277A2 Modification of feeding behavior |
| 01/26/2005 | EP1499206A1 Hydrothermically processed compositions containing phytosterols |
| 01/26/2005 | EP1499204A2 Physiologically compatible, phospholipid-containing, stable and hard matrix |
| 01/26/2005 | EP1499189A1 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |